down arrow

Vicore Pharma Holding AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0007577895
SEK
12.12
2.56 (26.78%)

Jun 25

OME

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Swedish Orphan Biovitrum AB
Swedencare AB
Camurus AB
Calliditas Therapeutics AB
BioArctic AB
Egetis Therapeutics AB
Vicore Pharma Holding AB
Hansa Biopharma AB
Xspray Pharma AB
Infant Bacterial Therapeutics AB
FluoGuide A/S

Why is Vicore Pharma Holding AB ?

1
The company has declared Negative results for the last 5 consecutive quarters
  • NET SALES(HY) At SEK 1.02 MM has Grown at -82.97%
  • OPERATING CASH FLOW(Y) Lowest at SEK -407.26 MM
  • NET PROFIT(HY) At SEK -245.72 MM has Grown at -25.62%
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 57.61%, its profits have fallen by -116.1%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vicore Pharma Holding AB for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Vicore Pharma Holding AB
-100.0%
-0.79
56.80%
OMX Stockholm 30
30.13%
1.89
15.95%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
56.87%
EBIT Growth (5y)
-201.69%
EBIT to Interest (avg)
-94.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.56
EV to EBIT
-4.86
EV to EBITDA
-4.86
EV to Capital Employed
-53.99
EV to Sales
236.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-53.15%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
RAW MATERIAL COST(Y)

Fallen by 0% (YoY

CASH AND EQV(HY)

Highest at SEK 2,226.53 MM

DEBT-EQUITY RATIO (HY)

Lowest at -106.95 %

PRE-TAX PROFIT(Q)

Highest at SEK -108.53 MM

NET PROFIT(Q)

Highest at SEK -108.62 MM

EPS(Q)

Highest at SEK -0.39

-17What is not working for the Company
NET SALES(HY)

At SEK 1.02 MM has Grown at -82.97%

OPERATING CASH FLOW(Y)

Lowest at SEK -407.26 MM

NET PROFIT(HY)

At SEK -245.72 MM has Grown at -25.62%

Here's what is working for Vicore Pharma Holding AB

Pre-Tax Profit
Highest at SEK -108.53 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Net Profit
Highest at SEK -108.62 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (SEK MM)

EPS
Highest at SEK -0.39
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (SEK)

Cash and Eqv
Highest at SEK 2,226.53 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -106.95 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Vicore Pharma Holding AB

Net Sales
At SEK 1.02 MM has Grown at -82.97%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (SEK MM)

Operating Cash Flow
Lowest at SEK -407.26 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (SEK MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."